Vicarious Surgical is a technology company.
Vicarious Surgical has raised $40.0M across 3 funding rounds.
Vicarious Surgical has raised $40.0M in total across 3 funding rounds.
Vicarious Surgical has raised $40.0M in total across 3 funding rounds.
Vicarious Surgical's investors include Dimension Capital, Garden City Companies, Innovation Endeavors, Lux Capital, Osage University Partners, The Column Group, UpHonest Capital, Bill Gates, Marc Benioff, Coral Capital, GFT Ventures, Nex Cubed.
# High-Level Overview
Vicarious Surgical is a medical robotics company developing next-generation surgical systems designed to make minimally invasive abdominal surgery safer, more efficient, and more accessible.[1][3] Founded in 2014, the company creates proprietary human-like robotic systems that enable surgeons to perform complex procedures through a single 1.5 cm incision, with the robot operating entirely inside the patient's body.[4] The company went public under the ticker RBOT and is currently advancing toward clinical deployment of its surgical platform.
The company's core mission is to improve patient outcomes, enhance surgeon capability, and increase healthcare efficiency through disruptive robotic technology.[1] Vicarious Surgical targets a significant market opportunity in abdominal procedures—particularly ventral hernia repair—where existing robotic solutions may be less suitable or cost-prohibitive.[1] The system is designed to reduce complication rates from the typical 15-20% associated with open surgery incisions down to approximately 1% through minimally invasive access.[6]
# Origin Story
Vicarious Surgical was founded in 2014 by Adam Sachs, Sammy Khalifa, and Dr. Barry Greene, who met as undergraduates at MIT.[2] The founders' vision was inspired by the science fiction film *Fantastic Voyage*, in which doctors shrink to travel within the human body—they sought to enable surgeons to achieve a similar capability through robotic systems.[3] Dr. Greene brought 25 years of experience performing advanced laparoscopic surgical procedures, providing critical clinical insight that shaped the robot's design.[2]
The company has achieved significant early validation: it received FDA Breakthrough Device Designation, a milestone recognition that accelerates the regulatory pathway toward commercialization.[3] By 2022, Vicarious Surgical was recognized by TIME magazine as one of the 200 best inventions of that year, and the company announced plans to introduce its $1.2 million system to hospitals as early as 2024.[6] More recently, the company established Center of Excellence agreements with HCA Healthcare and University Hospitals, positioning leading health systems as early adopters and collaborative partners in refining the technology.[5]
# Core Differentiators
# Role in the Broader Tech Landscape
Vicarious Surgical operates at the intersection of surgical robotics, minimally invasive medicine, and healthcare cost reduction—three converging trends reshaping modern surgery. The company addresses a critical gap: while robotic surgery systems exist (notably da Vinci), they remain expensive, require large incisions, and are not universally accessible across hospital networks.[1]
The timing is particularly favorable as healthcare systems face mounting pressure to reduce costs while improving patient outcomes. Minimally invasive approaches demonstrably reduce complications, shorten recovery times, and lower overall healthcare expenditures—creating strong economic incentives for adoption.[4] Vicarious Surgical's focus on common procedures like ventral hernia repair—high-volume surgeries performed across thousands of hospitals—positions the company to capture significant market share if clinical adoption succeeds.
The company also influences the broader medtech ecosystem by demonstrating that venture-backed startups can compete in regulated, capital-intensive surgical robotics markets traditionally dominated by established players like Intuitive Surgical. Their FDA Breakthrough designation and partnerships with major health systems signal that innovation in this space remains viable and valued.
# Quick Take & Future Outlook
Vicarious Surgical stands at an inflection point. The company has cleared critical regulatory and validation hurdles—FDA recognition and partnerships with leading health systems—positioning it for clinical deployment and market entry in the coming years. Success hinges on three factors: demonstrating clear clinical superiority over existing approaches, achieving reliable and cost-effective manufacturing at scale, and convincing surgeons and hospital administrators to adopt a new system despite switching costs and familiarity with established platforms.[1]
The broader trend favoring minimally invasive, cost-effective surgery works in Vicarious Surgical's favor. If the company successfully commercializes its system and achieves surgeon adoption, it could reshape abdominal surgery practice globally—reducing patient complications, shortening recovery times, and lowering healthcare costs simultaneously. The company's influence will ultimately depend on execution: translating technological innovation into clinical adoption and sustainable business growth in a competitive medtech landscape.
Vicarious Surgical has raised $40.0M across 3 funding rounds. Most recently, it raised $13.0M Series A in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $13.0M Series A | Dimension Capital, Garden City Companies, Innovation Endeavors, Lux Capital, Osage University Partners, The Column Group, UpHonest Capital, Bill Gates, Marc Benioff | |
| Feb 1, 2019 | $10.0M Series A | Coral Capital, Dimension Capital, Garden City Companies, GFT Ventures, Innovation Endeavors, Lux Capital, Nex Cubed, Osage University Partners, Race Capital, The Column Group, Victor Young, William Adams | |
| Apr 1, 2018 | $17.0M Series A | Coral Capital, Dimension Capital, GFT Ventures, Innovation Endeavors, Lux Capital, Nex Cubed, Race Capital, The Column Group, Victor Young, William Adams |